peptides6155.com › Topic › Cardarine As Investigational Pparδ Agonist — 2026 Update

Cardarine As Investigational Pparδ Agonist — 2026 Update

By Editorial Desk · published 2025-11-14 · last reviewed 2026-01-01 · Topic

Metabolite is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-01-01. Numbers and descriptions here follow the published literature rather than marketing material.

Cardarine as Investigational PPARδ Agonist

The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.

Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.

Regulation and Detection

Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.

Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.

Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.

Cardarine at a glance

PropertyValueNotes
Common synonymsGW501516, GW-501516, GW 501516, endurobolNames vary in research and anti-doping documents.
Chemical classSynthetic PPARδ agonistSmall-molecule nuclear receptor ligand.
CAS Registry Number317318-70-0Identifier commonly associated with GW501516.
AppearanceWhite to off-white powderTypical for purified research material.
SolubilityLow in water; soluble in DMSO and ethanolOrganic solvents are common for laboratory stock solutions.

Identity and Pharmacological Classification

PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.

Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.

Related pages on this site

Regulation and Analytical Detection

Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.

Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.

Supporting material

=== Surface modification improving stability === Following the formation of porous silicon, its surface is covered with covalently bonded hydrogen. Although the hydrogen coated surface is sufficiently stable when exposed to inert atmosphere for a short period of time, prolonged exposure render the surface prone to oxidation by atmospheric oxygen. The oxidation promotes instability in the surface and is undesirable for many applications. Thus, several methods were developed to promote the surface stability of porous silicon. An approach that can be taken is through thermal oxidation. The process involves heating the silicon to a temperature above 1000 C to promote full oxidation of silicon. The method reportedly produced samples with good stability to aging and electronic surface passivation. Porous silicon exhibits a high degree of biocompatibility. The large surface area enables organic molecules to adhere well. It degrades to Orthosillicic acid (H4SiO4), which causes no harm to the body. This has opened potential applications in medicine such as a framework of the growth of bone.

On April 6, 2017, Pritzker announced his candidacy for the Democratic nomination for governor of Illinois. He was endorsed by Illinois Secretary of State Jesse White, Illinois Congressman Luis Gutiérrez, former Illinois Congressman Glenn Poshard, more than a dozen members of the Illinois General Assembly, 21 local labor unions, and the Illinois AFL–CIO. On August 10, 2017, Pritzker announced that his running mate would be freshman state representative and fellow Chicago resident Juliana Stratton. By December 2017, Pritzker had spent $42 million of his own money on his campaign without receiving funding from any other source. On March 20, 2018, he won the Democratic primary with 45.13% of the vote, defeating five opponents. On November 6, 2018, Pritzker defeated incumbent Republican governor Bruce Rauner in the general election, receiving 54.53% of the vote to Rauner's 38.83%. Pritzker was well ahead of Rauner in most polls from the summer of 2018 onward, and won by the largest margin in a gubernatorial race since 1994. Pritzker spent $171.5 million of his own money on his campaign, primarily on digital outreach, television advertising, and staff. Pritzker was inaugurated as Illinois's 43rd governor on January 14, 2019. With an estimated net worth of $3.6 billion in January 2019, he became the richest politician in the U.S. His second term in office began on January 9, 2023.

== Function == This gene, expressed in the pituitary, encodes a receptor for growth-hormone-releasing hormone. Binding of this hormone to the receptor leads to synthesis and release of growth hormone. Mutations in this gene have been associated with isolated growth-hormone deficiency (IGHD), also known as Dwarfism of Sindh, a disorder characterized by short stature. Many alternate transcriptional splice variants encoding different isoforms have been described, but only two have been characterized to date.

Other economic reforms passed by the government included the creation of a unified modern currency based on the Japanese yen, banking, commercial and tax laws, stock exchanges, and a communications network. Establishment of a modern institutional framework conductive to an advanced capitalist economy took time, but was completed by the 1890s, by which time the government had largely relinquished direct control of the modernization process, primarily for budgetary reasons. The Land Tax Reform of 1873 was another significant fiscal reform by the Meiji government, establishing the right of private land ownership for the first time in Japan's history. Many of the former daimyo, whose pensions had been paid in a lump sum, benefited greatly through investments they made in emerging industries. Those who had been informally involved in foreign trade before the Meiji Restoration also flourished. Old bakufu-serving firms that clung to their traditional ways failed in the new business environment. The industrial economy continued to expand rapidly, until about 1920, due to inputs of advanced Western technology and large private investments. By World War I, Japan had become a major industrial nation.

=== Pain Free Arthritis Exercises === Together with physiotherapists Kobi Schwartz and Danny Kelman, Dr. Mendes developed a system of painless 'reverse action' and 'gravity dependent' exercises to preserve Hip joint mobility. The system has been tested with rewarding results for more than twenty years. The term 'praying exercises' was chosen due to the similarity to movements during rituals in a variety of religions. Later was modified to 'Pain Free Exercises. The exercises move the joint in maximal range with painless motions, keeping low joint pressure, and lubricate the articular cartilage to maintain its viability by alternating light pressure.

Sources: en.wikipedia.org

Notes from published material

The crystal structure of catechol oxidase purified from Ipomoea batatas has been resolved in its active form in both the oxidized Cu(II)-Cu(II) state and the reduced Cu(I)-Cu(I) state. It is a globular, single domain monomeric enzyme that is approximately 55 by 45 by 45 Å in size and ellipsoid in shape. A four α-helix bundle comprises the enzyme core, which girds the active site containing the dicopper center. The nitrogens on the imidazole side chains of His88, His109, and His118 coordinate with the first catalytic copper while the nitrogens on the imidazole side chains on His240, His244 and His274 coordinate with the second catalytic copper ion. In the oxidized Cu(II)-Cu(II) state, each copper ion possesses a four coordinate trigonal pyramidal geometry, with the three histidine residues and a bridging hydroxide molecule forming the four ligands on each copper ion. Comparing the reduced (Cu(I)-Cu(I)) state with the native (Cu(II)-Cu(II)) state of the enzyme, the key difference is the distance between the two copper centers. In the oxidized Cu(II)-Cu(II) state, the Cu-Cu distance is 3.3 Å while in the reduced Cu(I)-Cu(I) state, the distance increases to 4.4 Å. While the active site of both tyrosinase and catechol oxidase contain the di-copper center, variations in each enzyme’s respective structure result in differing activity. In catechol oxidase, a phenylalanine side-chain (Phe261) is above one of the copper centers and prevents the substrate from coordinating with both copper ions in the active site.

== Further reading == Buzuev, Vladimir; Gorodnov, Vladimir (1987). What Is Marxism–Leninism?. Moscow: Progress Publishers. "Marxism–Leninism". Encyclopedia of Marxism. Marxists Internet Archive. Retrieved 31 December 2020. Kuusinen, Otto Will (1963). Fundamentals of Marxism–Leninism. Translated by Dutt, Clemens (2nd rev. ed.). Moscow: Foreign Languages Publishing House. OCLC 1091006. OL 5975949M. Kuusinen, Otto Will (2022). Fundamentals of Marxism–Leninism. Translated by Dutt, Clemens. United States: Marx Engels Lenin Press. ISBN 979-8-8114-4663-6. Sheptulin, Alexander. Marxist-Leninist Philosophy. Moscow: Progress Publishers. OL 2170371W. Stalin, Joseph (1924). "The Foundations of Leninism". Works. Vol. 6. Moscow: Foreign Languages Publishing House. pp. 71–196. Spirkin, Alexander (1990). Fundamentals of Philosophy. Translated by Syrovatkin, Sergei. Moscow: Progress Publishers. ISBN 978-5-0100-2582-3.

== Names == The adjective Müllerian is written either Müllerian or müllerian, depending on the governing style guide; the derived term with the prefix anti- is then anti-Müllerian, anti-müllerian, or antimüllerian. The Müllerian ducts are named after Johannes Peter Müller. A list of the names that have been used for the antimüllerian hormone is as follows. For the sake of simplicity, this list ignores some orthographic variations; for example, it gives only one row for "Müllerian-inhibiting hormone", although there are four acceptable stylings thereof (capital M or lowercase m, hyphen or space).

== See also == Abigail Alliance for Better Access to Developmental Drugs Animal drug Biologics license application Drug discovery FDA Fast Track Development Program Good Manufacturing Practice Inverse benefit law Lists of investigational drugs Orphan drug TOL101

Sources: en.wikipedia.org

Frequently asked questions

What is cardarine?

Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.

Is cardarine a steroid?

No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.

Why was cardarine not developed further?

Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.

Is cardarine legal?

Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.

Network